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INTRODUCTION
Between 1998 and 2018, 450,000 Americans have died of 
overdose from opioid use disorder (OUD).1 In wake of the 
pandemic, there was a 42% increase in opioid overdoses in May 
2020, compared with May 2019.2 The annual cost to society of 
prescription drug use disorder is estimated at $74 billion dollars.3
Despite the significant fiscal and societal burden of this disease, 
access to evidence-based treatments as outlined Federal Code 42 
and the American Society of Addiction Medicine remains limited.4
Of those who sought treatment for OUD in 2016, 38% were 
covered by Medicaid, while 20% were uninsured.5 In 2017, there 
were 2.3 million Americans with OUD, yet there was a 25% 
decrease in OUD treatment.6 By 2019, less than 17% of patient 
diagnosed with OUD received treatment.7 Given state variation in 
Medicaid coverage of OUD treatment and the most important 
barrier to treatment is inadequate insurance coverage, 
understanding state adoption policies for OUD treatment is crucial 
to addressing this public health crisis.7-8
HYPOTHESES
1. States with Medicaid expansion provide more insurance 
coverage options for evidence-based OUD treatments compared 
with states that not expanded Medicaid.
2. Limits on insurance coverage of OUD treatments are associated 
with higher death rates from opioid overdose.
METHODS
The Arizona State University IRB deemed the research was not 
human subjects research. Using secondary database analyses, data 
from 2018 were culled from the Kaiser Family Foundation, the 
Centers for Disease Control and Prevention, and the U.S. Census 
Bureau to examine Medicaid expansion and insurance coverage for 
OUD treatments. Relationships between OUD treatment coverage 
limits and overdose deaths from semisynthetic opioids (prescription 
opioids), synthetic opioids (Fentanyl), methadone and heroin were 
examined. Descriptive and non-parametric statistics (χ2, Pearson 
correlation, Mann Whitney U, and η2 analyses) were used to 
characterize the results.
RESULTS
Inpatient coverage was the most prevalent treatment available in all states 
(n=43, 84.3%). Outpatient coverage, in the forms of intensive therapy 
(x2=5.21,p=.04) and long-term therapy (x2=10.93,p=.001), was more likely in 
states with Medicaid expansion. There were no differences in coverage of 
inpatient and residential therapies between states with and without Medicaid 
expansion as noted in Table 1.
Table 1.
Medicaid expansion conferred coverage of more OUD treatment options. 
Figure 2. Number of OUD treatment options by Medicaid Expansion
Coverage limits on intensive outpatient coverage were associated with higher 
death rates from synthetic opioids (H(2) = 6.47, p=.039) and heroin (H(2)= 6.09, 
p= .048). The effect size identified a medium effect (η2= 0.17) on availability of 
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DISCUSSION
• Inpatient coverage is more prevalent than coverage for 
intensive outpatient and outpatient treatment in all 
states.
• Medicaid expansion is positively correlated with access 
to outpatient OUD therapies. This is important because 
inpatient treatment is 2.3 times more costly that 
outpatient care.9
• Medicaid expansion is associated with more options for 
OUD treatment.
• Limits on treatment coverage for OUD treatment is 
associated with higher death rates from synthetic opioids 
(Fentanyl) and heroin.
LIMITATIONS AND FURTHER RESEARCH
As is true with secondary database analyses, data definitions may 
change over time making longitudinal comparisons difficult. Data 
reported on states’ death certificates may list other etiologies of 
death, rather than opioid overdose, which may limit the 
generalizability of the study. Some states did not report deaths 
and or all treatment options. Given that there are 50 states 
(small sample size) the effect of Medicaid expansion on access to 
treatment had to be large in order show a statistical differences 
in overdose death rates. Further research should study of the 
limits related to medication coverage to inform policy future 
policies.
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